Format

Send to

Choose Destination
BMC Psychiatry. 2018 Jul 16;18(1):227. doi: 10.1186/s12888-018-1793-9.

Atorvastatin in the treatment of Lithium-induced nephrogenic diabetes insipidus: the protocol of a randomized controlled trial.

Author information

1
Geri-PARTy Research Group, Jewish General Hospital/Lady Davis Institute, McGill University, 4333 Cote Ste-Catherine, Montreal, QC, H3T, 1E4, Montreal, Canada. jfs702@mun.ca.
2
Geri-PARTy Research Group, Jewish General Hospital/Lady Davis Institute, McGill University, 4333 Cote Ste-Catherine, Montreal, QC, H3T, 1E4, Montreal, Canada.
3
Douglas Mental Health University Institute and Department of Psychiatry, McGill University, Montreal, Canada.
4
Department of Epidemiology, Biostatistics and Occupational Health, McGill University Health Centre, Montreal, Canada.
5
Division of Nephrology, University Health Network, University of Toronto (UofT), Toronto, Canada.
6
Department of Psychiatry, Centre for Addiction and Mental Health & Department of Psychiatry, University of Toronto, Toronto, Canada.
7
Department of Psychiatry, Sunnybrook Research Institute, University of Toronto, Toronto, Canada.
8
Department of Psychiatry, GGZ, Geest, Amsterdam, the Netherlands.
9
Department of Psychiatry, McGill University Health Centre, Montreal, Canada.
10
Department of Biomedicine, University of Aarhus, Aarhus, Denmark.
11
Division of Nephrology, University of Naples, Naples, Italy.

Abstract

BACKGROUND:

Lithium is the gold-standard treatment for bipolar disorder, is highly effective in treating major depressive disorder, and has anti-suicidal properties. However, clinicians are increasingly avoiding lithium largely due to fears of renal toxicity. Nephrogenic Diabetes Insipidus (NDI) occurs in 15-20% of lithium users and predicts a 2-3 times increased risk of chronic kidney disease (CKD). We recently found that use of statins is associated with lower NDI risk in a cross-sectional study. In this current paper, we describe the methodology of a randomized controlled trial (RCT) to treat lithium-induced NDI using atorvastatin.

METHODS:

We will conduct a 12-week, double-blind placebo-controlled RCT of atorvastatin for lithium-induced NDI at McGill University, Montreal, Canada. We will recruit 60 current lithium users, aged 18-85, who have indicators of NDI, which we defined as urine osmolality (UOsm) < 600 mOsm/kg after 10-h fluid restriction. We will randomize patients to atorvastatin (20 mg/day) or placebo for 12 weeks. We will examine whether this improves measures of NDI: UOsm and aquaporin (AQP2) excretion at 12-week follow-up, adjusted for baseline.

RESULTS:

Not applicable.

CONCLUSION:

The aim of this clinical trial is to provide preliminary data about the efficacy of atorvastatin in treating NDI. If successful, lithium could theoretically be used more safely in patients with a reduced subsequent risk of CKD, hypernatremia, and acute kidney injury (AKI). If future definitive trials confirm this, this could potentially allow more patients to benefit from lithium, while minimizing renal risk.

TRIAL REGISTRATION:

ClinicalTrials.gov NCT02967653 . Registered in February 2017.

KEYWORDS:

Atorvastatin; Kidney function; Lithium; Nephrogenic diabetes insipidus; Placebo; Randomized clinical trial; Urinary osmolality

PMID:
30012135
PMCID:
PMC6048831
DOI:
10.1186/s12888-018-1793-9
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center